Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
© Charité | Wiebke Peitz

Press release


Charité 2030: Innovation and systematic development

Back to Overview

You are here:

Rethinking Health

Presentation of "Strategy 2030 - Rethinking Health": Michael Müller, Governing Mayor of Berlin, Senator for Science and Research and Chairman of the Supervisory Board of Charité, and Prof. Dr. Heyo K. Kroemer, Chairman of the Board of Management of Charité. Photo: Peitz/Charité
Presentation of "Strategy 2030 - Rethinking Health": Michael Müller, Governing Mayor of Berlin, Senator for Science and Research and Chairman of the Supervisory Board of Charité, and Prof. Dr. Heyo K. Kroemer, Chairman of the Board of Management of Charité. Photo: Peitz/Charité

With its ‘Strategy 2030 – Rethinking Health’, Charité has set itself an ambitious agenda for the coming years. Its bold and innovative vision for pioneering developments within research, teaching and health care was presented today. The aim of this strategy is to position Charité as the leading academic institution in the core areas of training, research, translation, and medical care.

Charité wants to continue to take an active role in shaping developments within the field of biomedicine and the health care system, ensuring these are in the interest of the people of Berlin and the rest of Germany. Michael Müller, Governing Mayor of Berlin, Senator for Higher Education and Research and Chair of Charité’s Supervisory Board, emphasized: “Charité is a pivotal partner in our plan to develop Berlin into a leading health metropolis, one which will stand for medical progress, outstanding expertise and health care which is focused on meeting future needs. We have achieved a great deal together over the past few years and we are determined to continue down this path. Charité’s 2030 strategy acts as a compass and guide in this endeavor, and I am grateful to all those whose work – both now and in the future – will ensure that each step of this vision is implemented.” 

Launched by Prof. Dr. Heyo K. Kroemer and the other members of the Executive Board, the strategic planning process for the next ten years began last fall. A thorough analysis of the current situation, trends within the health care sector and data from internal interviews and surveys was used to identify and prioritize areas of particular interest. Their selection was guided by an emphasis on a value-based approach to health care development, the development of precision treatment and prevention solutions, and a focus on robust and relevant research results. The creation of a digitalization strategy also forms an integral part of this process.

Stressing that the need to focus on likely future developments is particularly stark during the current pandemic, Prof. Dr. Heyo K. Kroemer, Charité’s Chief Executive Officer, said: “The coming months, too, will be marked by the challenges of the COVID-19 pandemic, and Charité will be extremely busy – in medical care and in research. However, a challenging pandemic will throw into particularly sharp relief the critical importance of a sustainable strategy. The pandemic has also shown that an organization must be agile enough to quickly respond to wholly unexpected challenges without ever losing sight of what lies ahead.”

The result of this process has been a new goal and vision for Charité. The concept of ‘Rethinking Health’ sits at the heart of the organization’s 2030 strategy. The following six priority areas form the focus of this vision’s strategic direction and implementation over the next few years:

• ‘The Future of Medicine’ forms the core of Charité’s strategic plan. It focuses on the translation of research findings into clinical practice and the transfer of relevant knowledge to society as a whole. 

•  ‘Health Care’ encompasses a person-focused and evidence-based approach to maintaining and restoring health. Charité will pursue a complementary approach which combines the highest standards of academic medicine with community-based tertiary care.

•  ‘Innovation and Research’ stands for translation as the key feature of Charité and the use of strategic fields of research to define and enhance its research profile. 

•  ‘People and Education’ stands for diversity, equal opportunities, and professional development opportunities at Charité.

•  ‘Campuses, Infrastructure and Economic Viability’ stands for distinct, campus-specific profiles for each of Charité’s clinical sites and the targeted structural development of each campus.

•  ‘Internal Transformation’ stands for the reconfiguration of Charité’s organizational and management processes and the development and strengthening of its role as partner and expert.

The decision to reshape Charité’s strategic direction was prompted by a specific development, namely a growing need for change within the health care system as a consequence of demographic change, our approach to biomedical innovation and the need to address digitalization as this decade’s key challenge. The expectation is furthermore that both increasing global mobility and climate change will result in further consequences to human health, creating a fundamentally new set of challenges.

Explaining his vision for Charité – Universitätsmedizin Berlin, Prof. Kroemer added: “Charité will be a leader in the core areas of training, research, translation and medical care. Working alongside its partner institutions, Charité will drive developments within the regional and national health care systems. At the same time, it will be an innovative and economically viable organization.”  

Outlining the first and most important step in this development, Prof. Kroemer said: “We must work together to rethink health. Only together with our members of staff will we be able to move forward and achieve tangible long-term impact. This is why, over the next few weeks and months, our greatest emphasis will be on internal communication.”


Strategy 2030 

Download ‘Strategy 2030 – Rethinking Health’ (only in German)


Manuela Zingl
Corporate Spokesperson
Charité – Universitätsmedizin Berlin
t: +49 30 450 570 400

Back to Overview